JP2003514765A - 新規形質導入分子およびその使用方法 - Google Patents

Info

Publication number

JP2003514765A

JP2003514765A JP2000611079A JP2000611079A JP2003514765A JP 2003514765 A JP2003514765 A JP 2003514765A JP 2000611079 A JP2000611079 A JP 2000611079A JP 2000611079 A JP2000611079 A JP 2000611079A JP 2003514765 A JP2003514765 A JP 2003514765A

Authority

JP

Japan

Prior art keywords

protein

mammal

fusion

cells

molecule

Prior art date

1999-02-28

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 238000000034 method Methods 0.000 title claims abstract description 183
• 230000002463 transducing effect Effects 0.000 title claims description 56
• 230000004927 fusion Effects 0.000 claims abstract description 235
• 210000000056 organ Anatomy 0.000 claims abstract description 33
• 210000004027 cell Anatomy 0.000 claims description 439
• 108090000623 proteins and genes Proteins 0.000 claims description 286
• 235000018102 proteins Nutrition 0.000 claims description 282
• 102000004169 proteins and genes Human genes 0.000 claims description 282
• 108020001507 fusion proteins Proteins 0.000 claims description 272
• 102000037865 fusion proteins Human genes 0.000 claims description 270
• 238000010361 transduction Methods 0.000 claims description 230
• 230000026683 transduction Effects 0.000 claims description 218
• 238000003776 cleavage reaction Methods 0.000 claims description 172
• 230000007017 scission Effects 0.000 claims description 171
• 239000004365 Protease Substances 0.000 claims description 146
• 102000035195 Peptidases Human genes 0.000 claims description 140
• 108091005804 Peptidases Proteins 0.000 claims description 140
• 241000124008 Mammalia Species 0.000 claims description 129
• 235000001014 amino acid Nutrition 0.000 claims description 120
• 108090000765 processed proteins & peptides Proteins 0.000 claims description 115
• 150000001413 amino acids Chemical class 0.000 claims description 113
• 244000052769 pathogen Species 0.000 claims description 112
• 241000725303 Human immunodeficiency virus Species 0.000 claims description 102
• 230000001717 pathogenic effect Effects 0.000 claims description 86
• 239000003814 drug Substances 0.000 claims description 70
• 230000001472 cytotoxic effect Effects 0.000 claims description 69
• 231100000433 cytotoxic Toxicity 0.000 claims description 68
• 102000010911 Enzyme Precursors Human genes 0.000 claims description 67
• 108010062466 Enzyme Precursors Proteins 0.000 claims description 67
• 229940079593 drug Drugs 0.000 claims description 62
• 108020004414 DNA Proteins 0.000 claims description 47
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 46
• 210000001519 tissue Anatomy 0.000 claims description 45
• 102100029855 Caspase-3 Human genes 0.000 claims description 44
• 239000012634 fragment Substances 0.000 claims description 43
• 102000004190 Enzymes Human genes 0.000 claims description 39
• 108090000790 Enzymes Proteins 0.000 claims description 39
• 229940088598 enzyme Drugs 0.000 claims description 39
• 241000700605 Viruses Species 0.000 claims description 35
• 238000011282 treatment Methods 0.000 claims description 34
• 208000015181 infectious disease Diseases 0.000 claims description 33
• 108010010369 HIV Protease Proteins 0.000 claims description 31
• 230000001225 therapeutic effect Effects 0.000 claims description 31
• 239000004475 Arginine Substances 0.000 claims description 29
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 29
• 201000010099 disease Diseases 0.000 claims description 27
• 230000002147 killing effect Effects 0.000 claims description 25
• 231100000599 cytotoxic agent Toxicity 0.000 claims description 24
• 239000002619 cytotoxin Substances 0.000 claims description 24
• 238000012360 testing method Methods 0.000 claims description 24
• 101000793880 Homo sapiens Caspase-3 Proteins 0.000 claims description 23
• 108090000397 Caspase 3 Proteins 0.000 claims description 22
• 230000002708 enhancing effect Effects 0.000 claims description 22
• 235000004279 alanine Nutrition 0.000 claims description 21
• 230000027455 binding Effects 0.000 claims description 20
• 210000003169 central nervous system Anatomy 0.000 claims description 20
• 238000001727 in vivo Methods 0.000 claims description 20
• 241000288906 Primates Species 0.000 claims description 18
• 208000035475 disorder Diseases 0.000 claims description 18
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 17
• 238000003556 assay Methods 0.000 claims description 17
• 230000006378 damage Effects 0.000 claims description 17
• 102000011727 Caspases Human genes 0.000 claims description 16
• 108010076667 Caspases Proteins 0.000 claims description 16
• 210000004556 brain Anatomy 0.000 claims description 15
• 238000000338 in vitro Methods 0.000 claims description 15
• 230000003834 intracellular effect Effects 0.000 claims description 15
• 210000001428 peripheral nervous system Anatomy 0.000 claims description 15
• 101710112752 Cytotoxin Proteins 0.000 claims description 14
• 241000283984 Rodentia Species 0.000 claims description 13
• 230000035772 mutation Effects 0.000 claims description 13
• 241000699666 Mus <mouse, genus> Species 0.000 claims description 12
• 229960005486 vaccine Drugs 0.000 claims description 12
• -1 Mch5) Proteins 0.000 claims description 10
• 210000004369 blood Anatomy 0.000 claims description 10
• 239000008280 blood Substances 0.000 claims description 10
• 230000003197 catalytic effect Effects 0.000 claims description 10
• 208000024827 Alzheimer disease Diseases 0.000 claims description 9
• 241000700588 Human alphaherpesvirus 1 Species 0.000 claims description 9
• 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 9
• 239000003242 anti bacterial agent Substances 0.000 claims description 9
• 239000002246 antineoplastic agent Substances 0.000 claims description 9
• 244000005700 microbiome Species 0.000 claims description 9
• 239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 9
• 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 8
• 241000894006 Bacteria Species 0.000 claims description 8
• 102000004091 Caspase-8 Human genes 0.000 claims description 8
• 108090000538 Caspase-8 Proteins 0.000 claims description 8
• 208000031886 HIV Infections Diseases 0.000 claims description 8
• 241000711549 Hepacivirus C Species 0.000 claims description 8
• 230000002924 anti-infective effect Effects 0.000 claims description 8
• 102100035904 Caspase-1 Human genes 0.000 claims description 7
• 108090000426 Caspase-1 Proteins 0.000 claims description 7
• 102100025064 Cellular tumor antigen p53 Human genes 0.000 claims description 7
• 241000701022 Cytomegalovirus Species 0.000 claims description 7
• 241001465754 Metazoa Species 0.000 claims description 7
• 241000283973 Oryctolagus cuniculus Species 0.000 claims description 7
• 238000010171 animal model Methods 0.000 claims description 7
• 230000001580 bacterial effect Effects 0.000 claims description 7
• 230000003115 biocidal effect Effects 0.000 claims description 7
• 239000003795 chemical substances by application Substances 0.000 claims description 7
• 108700031308 Antennapedia Homeodomain Proteins 0.000 claims description 6
• 102100038902 Caspase-7 Human genes 0.000 claims description 6
• 241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 6
• 208000023105 Huntington disease Diseases 0.000 claims description 6
• 208000018737 Parkinson disease Diseases 0.000 claims description 6
• 102000006601 Thymidine Kinase Human genes 0.000 claims description 6
• 108020004440 Thymidine kinase Proteins 0.000 claims description 6
• 229960005475 antiinfective agent Drugs 0.000 claims description 6
• 230000008499 blood brain barrier function Effects 0.000 claims description 6
• 210000001218 blood-brain barrier Anatomy 0.000 claims description 6
• 229940002612 prodrug Drugs 0.000 claims description 6
• 239000000651 prodrug Substances 0.000 claims description 6
• 230000003612 virological effect Effects 0.000 claims description 6
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 5
• 241000233866 Fungi Species 0.000 claims description 5
• 101710192266 Tegument protein VP22 Proteins 0.000 claims description 5
• 239000004599 antimicrobial Substances 0.000 claims description 5
• 230000001413 cellular effect Effects 0.000 claims description 5
• 238000011160 research Methods 0.000 claims description 5
• 208000030507 AIDS Diseases 0.000 claims description 4
• 208000000044 Amnesia Diseases 0.000 claims description 4
• 108090000567 Caspase 7 Proteins 0.000 claims description 4
• 102100025597 Caspase-4 Human genes 0.000 claims description 4
• 208000026139 Memory disease Diseases 0.000 claims description 4
• 241000244206 Nematoda Species 0.000 claims description 4
• 208000012902 Nervous system disease Diseases 0.000 claims description 4
• 241000223960 Plasmodium falciparum Species 0.000 claims description 4
• 206010036631 Presenile dementia Diseases 0.000 claims description 4
• 206010038997 Retroviral infections Diseases 0.000 claims description 4
• 230000036983 biotransformation Effects 0.000 claims description 4
• 244000000013 helminth Species 0.000 claims description 4
• 239000012678 infectious agent Substances 0.000 claims description 4
• 230000006984 memory degeneration Effects 0.000 claims description 4
• 208000023060 memory loss Diseases 0.000 claims description 4
• 238000001742 protein purification Methods 0.000 claims description 4
• 238000012216 screening Methods 0.000 claims description 4
• 241001529453 unidentified herpesvirus Species 0.000 claims description 4
• 230000009385 viral infection Effects 0.000 claims description 4
• 102000000311 Cytosine Deaminase Human genes 0.000 claims description 3
• 108010080611 Cytosine Deaminase Proteins 0.000 claims description 3
• 102000001398 Granzyme Human genes 0.000 claims description 3
• 108060005986 Granzyme Proteins 0.000 claims description 3
• 241000713340 Human immunodeficiency virus 2 Species 0.000 claims description 3
• 229930182555 Penicillin Natural products 0.000 claims description 3
• JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 3
• 108091000054 Prion Proteins 0.000 claims description 3
• 102000029797 Prion Human genes 0.000 claims description 3
• 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims description 3
• 101710102803 Tumor suppressor ARF Proteins 0.000 claims description 3
• 208000036142 Viral infection Diseases 0.000 claims description 3
• 230000006399 behavior Effects 0.000 claims description 3
• 238000005520 cutting process Methods 0.000 claims description 3
• 208000006454 hepatitis Diseases 0.000 claims description 3
• 231100000283 hepatitis Toxicity 0.000 claims description 3
• 239000005556 hormone Substances 0.000 claims description 3
• 229940088597 hormone Drugs 0.000 claims description 3
• 239000003550 marker Substances 0.000 claims description 3
• 229940049954 penicillin Drugs 0.000 claims description 3
• 230000002265 prevention Effects 0.000 claims description 3
• 101150047706 CASP6 gene Proteins 0.000 claims description 2
• 102000004018 Caspase 6 Human genes 0.000 claims description 2
• 108090000425 Caspase 6 Proteins 0.000 claims description 2
• 102000004068 Caspase-10 Human genes 0.000 claims description 2
• 108090000572 Caspase-10 Proteins 0.000 claims description 2
• 102000004046 Caspase-2 Human genes 0.000 claims description 2
• 108090000552 Caspase-2 Proteins 0.000 claims description 2
• 101710090338 Caspase-4 Proteins 0.000 claims description 2
• 102100038916 Caspase-5 Human genes 0.000 claims description 2
• 101710090333 Caspase-5 Proteins 0.000 claims description 2
• 102100026550 Caspase-9 Human genes 0.000 claims description 2
• 108090000566 Caspase-9 Proteins 0.000 claims description 2
• 101000933112 Homo sapiens Caspase-4 Proteins 0.000 claims description 2
• 101000741014 Homo sapiens Caspase-7 Proteins 0.000 claims description 2
• 201000009906 Meningitis Diseases 0.000 claims description 2
• 206010027202 Meningitis bacterial Diseases 0.000 claims description 2
• 239000004098 Tetracycline Substances 0.000 claims description 2
• 108090000190 Thrombin Proteins 0.000 claims description 2
• AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 claims description 2
• 229960000723 ampicillin Drugs 0.000 claims description 2
• 230000000202 analgesic effect Effects 0.000 claims description 2
• 210000004102 animal cell Anatomy 0.000 claims description 2
• 230000003110 anti-inflammatory effect Effects 0.000 claims description 2
• 229940034982 antineoplastic agent Drugs 0.000 claims description 2
• 201000009904 bacterial meningitis Diseases 0.000 claims description 2
• 230000004071 biological effect Effects 0.000 claims description 2
• 230000007812 deficiency Effects 0.000 claims description 2
• 238000007877 drug screening Methods 0.000 claims description 2
• 230000002526 effect on cardiovascular system Effects 0.000 claims description 2
• 206010014599 encephalitis Diseases 0.000 claims description 2
• 239000002095 exotoxin Substances 0.000 claims description 2
• 231100000776 exotoxin Toxicity 0.000 claims description 2
• 210000000987 immune system Anatomy 0.000 claims description 2
• 230000004941 influx Effects 0.000 claims description 2
• 229920002704 polyhistidine Polymers 0.000 claims description 2
• 239000003419 rna directed dna polymerase inhibitor Substances 0.000 claims description 2
• 241000894007 species Species 0.000 claims description 2
• 238000010998 test method Methods 0.000 claims description 2
• 229960002180 tetracycline Drugs 0.000 claims description 2
• 229930101283 tetracycline Natural products 0.000 claims description 2
• 235000019364 tetracycline Nutrition 0.000 claims description 2
• 150000003522 tetracyclines Chemical class 0.000 claims description 2
• 229960004072 thrombin Drugs 0.000 claims description 2
• ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims 4
• 241000282693 Cercopithecidae Species 0.000 claims 3
• 239000003443 antiviral agent Substances 0.000 claims 3
• 101710132601 Capsid protein Proteins 0.000 claims 2
• 229930186147 Cephalosporin Natural products 0.000 claims 2
• 101710094648 Coat protein Proteins 0.000 claims 2
• 206010010904 Convulsion Diseases 0.000 claims 2
• 102100021181 Golgi phosphoprotein 3 Human genes 0.000 claims 2
• 108010034145 Helminth Proteins Proteins 0.000 claims 2
• 241000577090 Human DNA virus Species 0.000 claims 2
• 241001502974 Human gammaherpesvirus 8 Species 0.000 claims 2
• 101710125418 Major capsid protein Proteins 0.000 claims 2
• 101710141454 Nucleoprotein Proteins 0.000 claims 2
• 241000282577 Pan troglodytes Species 0.000 claims 2
• 101710083689 Probable capsid protein Proteins 0.000 claims 2
• 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 2
• 229940124587 cephalosporin Drugs 0.000 claims 2
• 150000001780 cephalosporins Chemical class 0.000 claims 2
• 229940127089 cytotoxic agent Drugs 0.000 claims 2
• 241001493065 dsRNA viruses Species 0.000 claims 2
• 206010015037 epilepsy Diseases 0.000 claims 2
• 229960003276 erythromycin Drugs 0.000 claims 2
• OTLLEIBWKHEHGU-UHFFFAOYSA-N 2-[5-[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-4-phosphonooxyhexanedioic acid Chemical compound C1=NC=2C(N)=NC=NC=2N1C(C(C1O)O)OC1COC1C(CO)OC(OC(C(O)C(OP(O)(O)=O)C(O)C(O)=O)C(O)=O)C(O)C1O OTLLEIBWKHEHGU-UHFFFAOYSA-N 0.000 claims 1
• 241000224489 Amoeba Species 0.000 claims 1
• 108010001478 Bacitracin Proteins 0.000 claims 1
• 208000035143 Bacterial infection Diseases 0.000 claims 1
• 206010027260 Meningitis viral Diseases 0.000 claims 1
• 229940122313 Nucleoside reverse transcriptase inhibitor Drugs 0.000 claims 1
• 241000282579 Pan Species 0.000 claims 1
• 241001631646 Papillomaviridae Species 0.000 claims 1
• 241000282520 Papio Species 0.000 claims 1
• 241000282405 Pongo abelii Species 0.000 claims 1
• 229940122803 Vinca alkaloid Drugs 0.000 claims 1
• 229940126575 aminoglycoside Drugs 0.000 claims 1
• LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 claims 1
• 229960003022 amoxicillin Drugs 0.000 claims 1
• 239000003098 androgen Substances 0.000 claims 1
• 239000000921 anthelmintic agent Substances 0.000 claims 1
• 230000000843 anti-fungal effect Effects 0.000 claims 1
• 230000000340 anti-metabolite Effects 0.000 claims 1
• 230000000259 anti-tumor effect Effects 0.000 claims 1
• 239000000059 antiamebic agent Substances 0.000 claims 1
• 229940121375 antifungal agent Drugs 0.000 claims 1
• 230000000890 antigenic effect Effects 0.000 claims 1
• 239000003409 antileprotic agent Substances 0.000 claims 1
• 229940100197 antimetabolite Drugs 0.000 claims 1
• 239000002256 antimetabolite Substances 0.000 claims 1
• 229960003071 bacitracin Drugs 0.000 claims 1
• 229930184125 bacitracin Natural products 0.000 claims 1
• CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 claims 1
• 208000022362 bacterial infectious disease Diseases 0.000 claims 1
• 239000003782 beta lactam antibiotic agent Substances 0.000 claims 1
• 230000000975 bioactive effect Effects 0.000 claims 1
• 210000004958 brain cell Anatomy 0.000 claims 1
• 208000015114 central nervous system disease Diseases 0.000 claims 1
• 230000000295 complement effect Effects 0.000 claims 1
• 230000003412 degenerative effect Effects 0.000 claims 1
• 206010013932 dyslexia Diseases 0.000 claims 1
• 210000003238 esophagus Anatomy 0.000 claims 1
• 229940011871 estrogen Drugs 0.000 claims 1
• 239000000262 estrogen Substances 0.000 claims 1
• 230000009395 genetic defect Effects 0.000 claims 1
• 230000002068 genetic effect Effects 0.000 claims 1
• 239000003667 hormone antagonist Substances 0.000 claims 1
• 231100000745 invertebrate toxin Toxicity 0.000 claims 1
• 210000004324 lymphatic system Anatomy 0.000 claims 1
• 229940042402 non-nucleoside reverse transcriptase inhibitor Drugs 0.000 claims 1
• 239000002726 nonnucleoside reverse transcriptase inhibitor Substances 0.000 claims 1
• LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 claims 1
• 208000020016 psychiatric disease Diseases 0.000 claims 1
• 150000003212 purines Chemical class 0.000 claims 1
• 150000003230 pyrimidines Chemical class 0.000 claims 1
• LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 claims 1
• 208000008864 scrapie Diseases 0.000 claims 1
• 229940124530 sulfonamide Drugs 0.000 claims 1
• 150000003456 sulfonamides Chemical class 0.000 claims 1
• IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 claims 1
• 229960001082 trimethoprim Drugs 0.000 claims 1
• 201000010044 viral meningitis Diseases 0.000 claims 1
• 239000002132 β-lactam antibiotic Substances 0.000 claims 1
• 229940124586 β-lactam antibiotics Drugs 0.000 claims 1
• IUCJMVBFZDHPDX-UHFFFAOYSA-N tretamine Chemical group C1CN1C1=NC(N2CC2)=NC(N2CC2)=N1 IUCJMVBFZDHPDX-UHFFFAOYSA-N 0.000 description 110
• 229940024606 amino acid Drugs 0.000 description 88
• 235000019419 proteases Nutrition 0.000 description 84
• 101710085003 Alpha-tubulin N-acetyltransferase Proteins 0.000 description 73
• 101710085461 Alpha-tubulin N-acetyltransferase 1 Proteins 0.000 description 73
• 101710175714 Tyrosine aminotransferase Proteins 0.000 description 73
• 102000004196 processed proteins & peptides Human genes 0.000 description 48
• 230000001775 anti-pathogenic effect Effects 0.000 description 38
• 239000013598 vector Substances 0.000 description 37
• 230000002223 anti-pathogen Effects 0.000 description 35
• 125000003275 alpha amino acid group Chemical group 0.000 description 34
• 210000001744 T-lymphocyte Anatomy 0.000 description 31
• 238000003752 polymerase chain reaction Methods 0.000 description 31
• 230000006907 apoptotic process Effects 0.000 description 29
• 230000000694 effects Effects 0.000 description 28
• 239000000203 mixture Substances 0.000 description 26
• 239000013615 primer Substances 0.000 description 24
• 238000004458 analytical method Methods 0.000 description 22
• 229920001184 polypeptide Polymers 0.000 description 22
• 235000009697 arginine Nutrition 0.000 description 21
• 125000005647 linker group Chemical group 0.000 description 21
• 150000007523 nucleic acids Chemical class 0.000 description 21
• 102100033254 Tumor suppressor ARF Human genes 0.000 description 20
• 150000001875 compounds Chemical class 0.000 description 20
• 241000699670 Mus sp. Species 0.000 description 18
• 102000039446 nucleic acids Human genes 0.000 description 18
• 108020004707 nucleic acids Proteins 0.000 description 18
• 230000004913 activation Effects 0.000 description 17
• 231100000331 toxic Toxicity 0.000 description 17
• 230000002588 toxic effect Effects 0.000 description 17
• NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 description 16
• 238000006467 substitution reaction Methods 0.000 description 16
• NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 description 15
• 230000006870 function Effects 0.000 description 15
• 229960000311 ritonavir Drugs 0.000 description 15
• XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 14
• 125000000539 amino acid group Chemical group 0.000 description 14
• 230000003013 cytotoxicity Effects 0.000 description 14
• 231100000135 cytotoxicity Toxicity 0.000 description 14
• 238000001943 fluorescence-activated cell sorting Methods 0.000 description 14
• 101150100916 Casp3 gene Proteins 0.000 description 13
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 11
• 241000700584 Simplexvirus Species 0.000 description 11
• 239000002253 acid Substances 0.000 description 11
• 238000007792 addition Methods 0.000 description 11
• 238000013459 approach Methods 0.000 description 11
• 239000002299 complementary DNA Substances 0.000 description 11
• 238000007796 conventional method Methods 0.000 description 11
• 238000004519 manufacturing process Methods 0.000 description 11
• 101150019028 Antp gene Proteins 0.000 description 10
• 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 10
• 230000008901 benefit Effects 0.000 description 10
• 238000010367 cloning Methods 0.000 description 10
• 210000000653 nervous system Anatomy 0.000 description 10
• 230000000144 pharmacologic effect Effects 0.000 description 10
• 239000002953 phosphate buffered saline Substances 0.000 description 10
• 238000010561 standard procedure Methods 0.000 description 10
• 239000000758 substrate Substances 0.000 description 10
• 241000282412 Homo Species 0.000 description 9
• 230000030833 cell death Effects 0.000 description 9
• 239000002609 medium Substances 0.000 description 9
• 125000003729 nucleotide group Chemical group 0.000 description 9
• 239000013612 plasmid Substances 0.000 description 9
• 238000002360 preparation method Methods 0.000 description 9
• 238000000746 purification Methods 0.000 description 9
• 239000000126 substance Substances 0.000 description 9
• 108010077850 Nuclear Localization Signals Proteins 0.000 description 8
• 108091034117 Oligonucleotide Proteins 0.000 description 8
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
• 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 8
• 230000022534 cell killing Effects 0.000 description 8
• 239000003153 chemical reaction reagent Substances 0.000 description 8
• 210000000805 cytoplasm Anatomy 0.000 description 8
• 230000001419 dependent effect Effects 0.000 description 8
• 238000002474 experimental method Methods 0.000 description 8
• 230000009931 harmful effect Effects 0.000 description 8
• 210000004962 mammalian cell Anatomy 0.000 description 8
• 239000002773 nucleotide Substances 0.000 description 8
• 238000002560 therapeutic procedure Methods 0.000 description 8
• 241000588724 Escherichia coli Species 0.000 description 7
• 206010028980 Neoplasm Diseases 0.000 description 7
• GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 7
• MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 7
• 239000000872 buffer Substances 0.000 description 7
• 239000004202 carbamide Substances 0.000 description 7
• 230000003833 cell viability Effects 0.000 description 7
• 238000006243 chemical reaction Methods 0.000 description 7
• 235000018417 cysteine Nutrition 0.000 description 7
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 7
• GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 7
• 230000006337 proteolytic cleavage Effects 0.000 description 7
• 230000010076 replication Effects 0.000 description 7
• 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 6
• 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 6
• 239000004472 Lysine Substances 0.000 description 6
• 108091028043 Nucleic acid sequence Proteins 0.000 description 6
• 101710149951 Protein Tat Proteins 0.000 description 6
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 6
• 229960004150 aciclovir Drugs 0.000 description 6
• 229940041181 antineoplastic drug Drugs 0.000 description 6
• 230000015572 biosynthetic process Effects 0.000 description 6
• 238000004587 chromatography analysis Methods 0.000 description 6
• 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 6
• 230000007717 exclusion Effects 0.000 description 6
• RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
• 230000006698 induction Effects 0.000 description 6
• 230000001939 inductive effect Effects 0.000 description 6
• 210000004072 lung Anatomy 0.000 description 6
• 201000004792 malaria Diseases 0.000 description 6
• 238000005259 measurement Methods 0.000 description 6
• 230000004048 modification Effects 0.000 description 6
• 238000012986 modification Methods 0.000 description 6
• 239000002777 nucleoside Substances 0.000 description 6
• 239000000523 sample Substances 0.000 description 6
• 208000037357 HIV infectious disease Diseases 0.000 description 5
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 5
• 230000036436 anti-hiv Effects 0.000 description 5
• 229940124599 anti-inflammatory drug Drugs 0.000 description 5
• 229940088710 antibiotic agent Drugs 0.000 description 5
• 239000007864 aqueous solution Substances 0.000 description 5
• 201000011510 cancer Diseases 0.000 description 5
• 239000002327 cardiovascular agent Substances 0.000 description 5
• 229940125692 cardiovascular agent Drugs 0.000 description 5
• 230000008859 change Effects 0.000 description 5
• 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 5
• 230000034994 death Effects 0.000 description 5
• 231100000517 death Toxicity 0.000 description 5
• 239000013604 expression vector Substances 0.000 description 5
• 238000000684 flow cytometry Methods 0.000 description 5
• 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 5
• 230000002458 infectious effect Effects 0.000 description 5
• 239000003112 inhibitor Substances 0.000 description 5
• 229920002521 macromolecule Polymers 0.000 description 5
• 229930182817 methionine Natural products 0.000 description 5
• 238000000386 microscopy Methods 0.000 description 5
• 210000003205 muscle Anatomy 0.000 description 5
• 210000004940 nucleus Anatomy 0.000 description 5
• 239000002245 particle Substances 0.000 description 5
• 238000012545 processing Methods 0.000 description 5
• 239000000047 product Substances 0.000 description 5
• 150000003431 steroids Chemical class 0.000 description 5
• 230000014616 translation Effects 0.000 description 5
• 230000035899 viability Effects 0.000 description 5
• 239000011782 vitamin Substances 0.000 description 5
• 229940088594 vitamin Drugs 0.000 description 5
• 235000013343 vitamin Nutrition 0.000 description 5
• 229930003231 vitamin Natural products 0.000 description 5
• 208000035473 Communicable disease Diseases 0.000 description 4
• 102000053602 DNA Human genes 0.000 description 4
• HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 4
• 241000238631 Hexapoda Species 0.000 description 4
• 239000013543 active substance Substances 0.000 description 4
• 230000003321 amplification Effects 0.000 description 4
• 229940035676 analgesics Drugs 0.000 description 4
• 229940035674 anesthetics Drugs 0.000 description 4
• 239000000730 antalgic agent Substances 0.000 description 4
• 102000055102 bcl-2-Associated X Human genes 0.000 description 4
• 230000015556 catabolic process Effects 0.000 description 4
• 238000004113 cell culture Methods 0.000 description 4
• 230000003196 chaotropic effect Effects 0.000 description 4
• 210000004748 cultured cell Anatomy 0.000 description 4
• 238000006731 degradation reaction Methods 0.000 description 4
• 238000011161 development Methods 0.000 description 4
• 230000018109 developmental process Effects 0.000 description 4
• 238000009472 formulation Methods 0.000 description 4
• 239000003193 general anesthetic agent Substances 0.000 description 4
• 239000004030 hiv protease inhibitor Substances 0.000 description 4
• 238000003119 immunoblot Methods 0.000 description 4
• 239000007924 injection Substances 0.000 description 4
• 238000002347 injection Methods 0.000 description 4
• 239000007928 intraperitoneal injection Substances 0.000 description 4
• 238000012933 kinetic analysis Methods 0.000 description 4
• 150000002632 lipids Chemical class 0.000 description 4
• 239000002502 liposome Substances 0.000 description 4
• 230000035800 maturation Effects 0.000 description 4
• 238000003199 nucleic acid amplification method Methods 0.000 description 4
• 150000003833 nucleoside derivatives Chemical class 0.000 description 4
• 230000036961 partial effect Effects 0.000 description 4
• 239000000813 peptide hormone Substances 0.000 description 4
• 230000001737 promoting effect Effects 0.000 description 4
• 230000017854 proteolysis Effects 0.000 description 4
• 230000002829 reductive effect Effects 0.000 description 4
• 108091008146 restriction endonucleases Proteins 0.000 description 4
• 239000011780 sodium chloride Substances 0.000 description 4
• 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
• 239000000243 solution Substances 0.000 description 4
• 210000000952 spleen Anatomy 0.000 description 4
• 239000003270 steroid hormone Substances 0.000 description 4
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
• 108700000712 BH3 Interacting Domain Death Agonist Proteins 0.000 description 3
• 102000055105 BH3 Interacting Domain Death Agonist Human genes 0.000 description 3
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
• 241000196324 Embryophyta Species 0.000 description 3
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
• 102000003886 Glycoproteins Human genes 0.000 description 3
• 108090000288 Glycoproteins Proteins 0.000 description 3
• 239000007995 HEPES buffer Substances 0.000 description 3
• 229940122440 HIV protease inhibitor Drugs 0.000 description 3
• 208000007514 Herpes zoster Diseases 0.000 description 3
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
• ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 3
• 241000208474 Protea Species 0.000 description 3
• 108050002653 Retinoblastoma protein Proteins 0.000 description 3
• 230000009471 action Effects 0.000 description 3
• 239000008186 active pharmaceutical agent Substances 0.000 description 3
• 239000000427 antigen Substances 0.000 description 3
• 108010008124 aspartyl-glutamyl-valyl-aspartyl-7-amino-4-trifluoromethylcoumarin Proteins 0.000 description 3
• 108010005774 beta-Galactosidase Proteins 0.000 description 3
• 210000000601 blood cell Anatomy 0.000 description 3
• 230000037396 body weight Effects 0.000 description 3
• 229940098773 bovine serum albumin Drugs 0.000 description 3
• 210000003855 cell nucleus Anatomy 0.000 description 3
• 238000003570 cell viability assay Methods 0.000 description 3
• 238000005119 centrifugation Methods 0.000 description 3
• 238000004440 column chromatography Methods 0.000 description 3
• 238000004624 confocal microscopy Methods 0.000 description 3
• 238000004132 cross linking Methods 0.000 description 3
• 230000001086 cytosolic effect Effects 0.000 description 3
• 238000004925 denaturation Methods 0.000 description 3
• 230000036425 denaturation Effects 0.000 description 3
• 238000003745 diagnosis Methods 0.000 description 3
• 229940088679 drug related substance Drugs 0.000 description 3
• 210000003527 eukaryotic cell Anatomy 0.000 description 3
• 239000012530 fluid Substances 0.000 description 3
• 238000001502 gel electrophoresis Methods 0.000 description 3
• 210000002865 immune cell Anatomy 0.000 description 3
• 230000036039 immunity Effects 0.000 description 3
• 210000003000 inclusion body Anatomy 0.000 description 3
• 150000002605 large molecules Chemical class 0.000 description 3
• 230000007246 mechanism Effects 0.000 description 3
• 230000000813 microbial effect Effects 0.000 description 3
• 230000007935 neutral effect Effects 0.000 description 3
• 238000010647 peptide synthesis reaction Methods 0.000 description 3
• 230000008092 positive effect Effects 0.000 description 3
• 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 3
• 230000000069 prophylactic effect Effects 0.000 description 3
• 230000002285 radioactive effect Effects 0.000 description 3
• 230000006798 recombination Effects 0.000 description 3
• 238000005215 recombination Methods 0.000 description 3
• 239000002904 solvent Substances 0.000 description 3
• 238000000527 sonication Methods 0.000 description 3
• 238000001228 spectrum Methods 0.000 description 3
• 239000003381 stabilizer Substances 0.000 description 3
• 230000004083 survival effect Effects 0.000 description 3
• 208000024891 symptom Diseases 0.000 description 3
• 229940124597 therapeutic agent Drugs 0.000 description 3
• 238000013518 transcription Methods 0.000 description 3
• 230000035897 transcription Effects 0.000 description 3
• 238000001890 transfection Methods 0.000 description 3
• 238000012546 transfer Methods 0.000 description 3
• 238000013519 translation Methods 0.000 description 3
• 241001430294 unidentified retrovirus Species 0.000 description 3
• RAVVEEJGALCVIN-AGVBWZICSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-6-amino-2-[[(2s)-2-[[2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]hexanoyl]amino]-5-(diamino Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CNC(=O)[C@@H](N)CC1=CC=C(O)C=C1 RAVVEEJGALCVIN-AGVBWZICSA-N 0.000 description 2
• 101710112984 20 kDa protein Proteins 0.000 description 2
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
• 241000282472 Canis lupus familiaris Species 0.000 description 2
• 108091026890 Coding region Proteins 0.000 description 2
• 102000003910 Cyclin D Human genes 0.000 description 2
• 108090000259 Cyclin D Proteins 0.000 description 2
• 102000013701 Cyclin-Dependent Kinase 4 Human genes 0.000 description 2
• 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 2
• 102100038026 DNA fragmentation factor subunit alpha Human genes 0.000 description 2
• 101710182628 DNA fragmentation factor subunit alpha Proteins 0.000 description 2
• 102100038023 DNA fragmentation factor subunit beta Human genes 0.000 description 2
• 239000003155 DNA primer Substances 0.000 description 2
• 230000007018 DNA scission Effects 0.000 description 2
• BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
• 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
• 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
• 208000009889 Herpes Simplex Diseases 0.000 description 2
• 101000619542 Homo sapiens E3 ubiquitin-protein ligase parkin Proteins 0.000 description 2
• 241000598436 Human T-cell lymphotropic virus Species 0.000 description 2
• 241000701085 Human alphaherpesvirus 3 Species 0.000 description 2
• 108010016183 Human immunodeficiency virus 1 p16 protease Proteins 0.000 description 2
• 206010061598 Immunodeficiency Diseases 0.000 description 2
• 208000029462 Immunodeficiency disease Diseases 0.000 description 2
• 102000015696 Interleukins Human genes 0.000 description 2
• 108010063738 Interleukins Proteins 0.000 description 2
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
• 101710159910 Movement protein Proteins 0.000 description 2
• 101000802812 Mus musculus BH3-interacting domain death agonist Proteins 0.000 description 2
• 108010021466 Mutant Proteins Proteins 0.000 description 2
• 102000008300 Mutant Proteins Human genes 0.000 description 2
• 206010028851 Necrosis Diseases 0.000 description 2
• 238000012408 PCR amplification Methods 0.000 description 2
• 229910019142 PO4 Inorganic materials 0.000 description 2
• 108091000080 Phosphotransferase Proteins 0.000 description 2
• 241000224016 Plasmodium Species 0.000 description 2
• LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
• 239000012979 RPMI medium Substances 0.000 description 2
• 241000700159 Rattus Species 0.000 description 2
• 108020004511 Recombinant DNA Proteins 0.000 description 2
• 108010039491 Ricin Proteins 0.000 description 2
• IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
• 206010052779 Transplant rejections Diseases 0.000 description 2
• 101710090398 Viral interleukin-10 homolog Proteins 0.000 description 2
• 239000012190 activator Substances 0.000 description 2
• 239000000443 aerosol Substances 0.000 description 2
• 238000001042 affinity chromatography Methods 0.000 description 2
• 230000004075 alteration Effects 0.000 description 2
• 239000002259 anti human immunodeficiency virus agent Substances 0.000 description 2
• 108091007433 antigens Proteins 0.000 description 2
• 102000036639 antigens Human genes 0.000 description 2
• 239000003430 antimalarial agent Substances 0.000 description 2
• 239000012062 aqueous buffer Substances 0.000 description 2
• 101150016874 asp3 gene Proteins 0.000 description 2
• 210000001185 bone marrow Anatomy 0.000 description 2
• 239000007975 buffered saline Substances 0.000 description 2
• 210000004899 c-terminal region Anatomy 0.000 description 2
• 239000002775 capsule Substances 0.000 description 2
• 150000001720 carbohydrates Chemical class 0.000 description 2
• 235000014633 carbohydrates Nutrition 0.000 description 2
• 239000006143 cell culture medium Substances 0.000 description 2
• 210000000170 cell membrane Anatomy 0.000 description 2
• 230000012292 cell migration Effects 0.000 description 2
• 238000010382 chemical cross-linking Methods 0.000 description 2
• 238000007385 chemical modification Methods 0.000 description 2
• OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
• 230000007123 defense Effects 0.000 description 2
• 230000002950 deficient Effects 0.000 description 2
• 238000012217 deletion Methods 0.000 description 2
• 230000037430 deletion Effects 0.000 description 2
• 238000011033 desalting Methods 0.000 description 2
• 238000001514 detection method Methods 0.000 description 2
• 238000000502 dialysis Methods 0.000 description 2
• 235000014113 dietary fatty acids Nutrition 0.000 description 2
• 239000000975 dye Substances 0.000 description 2
• 238000001962 electrophoresis Methods 0.000 description 2
• 210000000981 epithelium Anatomy 0.000 description 2
• 238000013401 experimental design Methods 0.000 description 2
• 229930195729 fatty acid Natural products 0.000 description 2
• 239000000194 fatty acid Substances 0.000 description 2
• 210000002950 fibroblast Anatomy 0.000 description 2
• 239000007850 fluorescent dye Substances 0.000 description 2
• 239000003205 fragrance Substances 0.000 description 2
• 210000001035 gastrointestinal tract Anatomy 0.000 description 2
• 239000000499 gel Substances 0.000 description 2
• 238000002523 gelfiltration Methods 0.000 description 2
• 239000011521 glass Substances 0.000 description 2
• 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 2
• 239000005090 green fluorescent protein Substances 0.000 description 2
• 230000009848 hypophosphorylation Effects 0.000 description 2
• 230000037451 immune surveillance Effects 0.000 description 2
• 230000007813 immunodeficiency Effects 0.000 description 2
• 230000001976 improved effect Effects 0.000 description 2
• 238000010348 incorporation Methods 0.000 description 2
• 230000001965 increasing effect Effects 0.000 description 2
• 230000006882 induction of apoptosis Effects 0.000 description 2
• 201000006747 infectious mononucleosis Diseases 0.000 description 2
• 206010022000 influenza Diseases 0.000 description 2
• 230000002401 inhibitory effect Effects 0.000 description 2
• 238000007912 intraperitoneal administration Methods 0.000 description 2
• 238000002955 isolation Methods 0.000 description 2
• 210000003734 kidney Anatomy 0.000 description 2
• 239000008101 lactose Substances 0.000 description 2
• 231100000518 lethal Toxicity 0.000 description 2
• 230000001665 lethal effect Effects 0.000 description 2
• 230000000670 limiting effect Effects 0.000 description 2
• 230000004807 localization Effects 0.000 description 2
• 230000033001 locomotion Effects 0.000 description 2
• 210000004698 lymphocyte Anatomy 0.000 description 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
• 238000007726 management method Methods 0.000 description 2
• BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
• 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 2
• 235000013336 milk Nutrition 0.000 description 2
• 239000008267 milk Substances 0.000 description 2
• 210000004080 milk Anatomy 0.000 description 2
• 210000003470 mitochondria Anatomy 0.000 description 2
• 238000010369 molecular cloning Methods 0.000 description 2
• 230000017074 necrotic cell death Effects 0.000 description 2
• 125000003835 nucleoside group Chemical group 0.000 description 2
• 235000015097 nutrients Nutrition 0.000 description 2
• 230000036407 pain Effects 0.000 description 2
• 102000045222 parkin Human genes 0.000 description 2
• 230000037361 pathway Effects 0.000 description 2
• 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 2
• 239000010452 phosphate Substances 0.000 description 2
• 102000020233 phosphotransferase Human genes 0.000 description 2
• 229920000642 polymer Polymers 0.000 description 2
• 238000001556 precipitation Methods 0.000 description 2
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
• 235000019833 protease Nutrition 0.000 description 2
• 230000002797 proteolythic effect Effects 0.000 description 2
• 208000028172 protozoa infectious disease Diseases 0.000 description 2
• 238000011002 quantification Methods 0.000 description 2
• 238000010188 recombinant method Methods 0.000 description 2
• 230000003362 replicative effect Effects 0.000 description 2
• 150000003839 salts Chemical class 0.000 description 2
• 238000004062 sedimentation Methods 0.000 description 2
• 235000012239 silicon dioxide Nutrition 0.000 description 2
• 150000003384 small molecules Chemical class 0.000 description 2
• 210000004989 spleen cell Anatomy 0.000 description 2
• 238000010911 splenectomy Methods 0.000 description 2
• 238000007447 staining method Methods 0.000 description 2
• 239000000725 suspension Substances 0.000 description 2
• 238000003786 synthesis reaction Methods 0.000 description 2
• 239000000454 talc Substances 0.000 description 2
• 229910052623 talc Inorganic materials 0.000 description 2
• 235000012222 talc Nutrition 0.000 description 2
• YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 2
• 238000011144 upstream manufacturing Methods 0.000 description 2
• 210000002845 virion Anatomy 0.000 description 2
• WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
• LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
• BJFILYACUCTLKB-UHFFFAOYSA-N 2-chloroguanidine Chemical compound NC(N)=NCl BJFILYACUCTLKB-UHFFFAOYSA-N 0.000 description 1
• HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
• OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
• 108010066676 Abrin Proteins 0.000 description 1
• 208000029483 Acquired immunodeficiency Diseases 0.000 description 1
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
• 108020005544 Antisense RNA Proteins 0.000 description 1
• 241000269350 Anura Species 0.000 description 1
• 102000007272 Apoptosis Inducing Factor Human genes 0.000 description 1
• 108010033604 Apoptosis Inducing Factor Proteins 0.000 description 1
• 102000010565 Apoptosis Regulatory Proteins Human genes 0.000 description 1
• 108010063104 Apoptosis Regulatory Proteins Proteins 0.000 description 1
• 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
• 101800001109 Assemblin Proteins 0.000 description 1
• 241000271566 Aves Species 0.000 description 1
• 231100000699 Bacterial toxin Toxicity 0.000 description 1
• 101150017888 Bcl2 gene Proteins 0.000 description 1
• DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
• 102100026189 Beta-galactosidase Human genes 0.000 description 1
• 108010017384 Blood Proteins Proteins 0.000 description 1
• 102000004506 Blood Proteins Human genes 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• 208000011691 Burkitt lymphomas Diseases 0.000 description 1
• 108090000994 Catalytic RNA Proteins 0.000 description 1
• 102000053642 Catalytic RNA Human genes 0.000 description 1
• 102000009016 Cholera Toxin Human genes 0.000 description 1
• 108010049048 Cholera Toxin Proteins 0.000 description 1
• 206010008748 Chorea Diseases 0.000 description 1
• 108010077544 Chromatin Proteins 0.000 description 1
• 108090000317 Chymotrypsin Proteins 0.000 description 1
• 235000001258 Cinchona calisaya Nutrition 0.000 description 1
• 108020004705 Codon Proteins 0.000 description 1
• 229920002261 Corn starch Polymers 0.000 description 1
• 102100030497 Cytochrome c Human genes 0.000 description 1
• 108010075031 Cytochromes c Proteins 0.000 description 1
• 102000004127 Cytokines Human genes 0.000 description 1
• 108090000695 Cytokines Proteins 0.000 description 1
• 108020001019 DNA Primers Proteins 0.000 description 1
• 230000005778 DNA damage Effects 0.000 description 1
• 231100000277 DNA damage Toxicity 0.000 description 1
• 230000004543 DNA replication Effects 0.000 description 1
• 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
• 101710096438 DNA-binding protein Proteins 0.000 description 1
• 101100382568 Danio rerio caspa gene Proteins 0.000 description 1
• 206010011906 Death Diseases 0.000 description 1
• 229920002307 Dextran Polymers 0.000 description 1
• 108010053187 Diphtheria Toxin Proteins 0.000 description 1
• 102000016607 Diphtheria Toxin Human genes 0.000 description 1
• 101800000585 Diphtheria toxin fragment A Proteins 0.000 description 1
• 241000255925 Diptera Species 0.000 description 1
• 101100284769 Drosophila melanogaster hemo gene Proteins 0.000 description 1
• 206010059866 Drug resistance Diseases 0.000 description 1
• 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 description 1
• 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 description 1
• 241000709661 Enterovirus Species 0.000 description 1
• 241000283086 Equidae Species 0.000 description 1
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
• 108091092566 Extrachromosomal DNA Proteins 0.000 description 1
• 241000701087 Felid alphaherpesvirus 1 Species 0.000 description 1
• 241000282326 Felis catus Species 0.000 description 1
• 102000009123 Fibrin Human genes 0.000 description 1
• 108010073385 Fibrin Proteins 0.000 description 1
• BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
• 201000008808 Fibrosarcoma Diseases 0.000 description 1
• 241000710781 Flaviviridae Species 0.000 description 1
• 241000710831 Flavivirus Species 0.000 description 1
• 101710177291 Gag polyprotein Proteins 0.000 description 1
• 108010010803 Gelatin Proteins 0.000 description 1
• 108700004714 Gelonium multiflorum GEL Proteins 0.000 description 1
• 241001272178 Glires Species 0.000 description 1
• 239000004471 Glycine Substances 0.000 description 1
• 229930186217 Glycolipid Natural products 0.000 description 1
• 208000027814 HTLV-2 infection Diseases 0.000 description 1
• 241000125500 Hedypnois rhagadioloides Species 0.000 description 1
• 208000004898 Herpes Labialis Diseases 0.000 description 1
• 208000000903 Herpes simplex encephalitis Diseases 0.000 description 1
• 208000037018 Herpes simplex virus encephalitis Diseases 0.000 description 1
• 208000029433 Herpesviridae infectious disease Diseases 0.000 description 1
• 108010048671 Homeodomain Proteins Proteins 0.000 description 1
• 102000009331 Homeodomain Proteins Human genes 0.000 description 1
• 101000950965 Homo sapiens DNA fragmentation factor subunit beta Proteins 0.000 description 1
• 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
• 108010070875 Human Immunodeficiency Virus tat Gene Products Proteins 0.000 description 1
• 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 1
• 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
• 241000701027 Human herpesvirus 6 Species 0.000 description 1
• 108700000788 Human immunodeficiency virus 1 tat peptide (47-57) Proteins 0.000 description 1
• 102100034343 Integrase Human genes 0.000 description 1
• 102000014150 Interferons Human genes 0.000 description 1
• 108010050904 Interferons Proteins 0.000 description 1
• 102000000588 Interleukin-2 Human genes 0.000 description 1
• 108010002350 Interleukin-2 Proteins 0.000 description 1
• 241001138401 Kluyveromyces lactis Species 0.000 description 1
• 241000235058 Komagataella pastoris Species 0.000 description 1
• 241000254158 Lampyridae Species 0.000 description 1
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
• HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
• 241000406668 Loxodonta cyclotis Species 0.000 description 1
• 108060001084 Luciferase Proteins 0.000 description 1
• 239000005089 Luciferase Substances 0.000 description 1
• 102000004317 Lyases Human genes 0.000 description 1
• 108090000856 Lyases Proteins 0.000 description 1
• 206010025323 Lymphomas Diseases 0.000 description 1
• 101800000577 Maturation protease Proteins 0.000 description 1
• 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
• 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
• 208000009869 Neu-Laxova syndrome Diseases 0.000 description 1
• 108091005461 Nucleic proteins Proteins 0.000 description 1
• 206010067152 Oral herpes Diseases 0.000 description 1
• 241000282376 Panthera tigris Species 0.000 description 1
• 229930040373 Paraformaldehyde Natural products 0.000 description 1
• 241001494479 Pecora Species 0.000 description 1
• JNTOCHDNEULJHD-UHFFFAOYSA-N Penciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(CCC(CO)CO)C=N2 JNTOCHDNEULJHD-UHFFFAOYSA-N 0.000 description 1
• 241000287463 Phalacrocorax Species 0.000 description 1
• 102000015439 Phospholipases Human genes 0.000 description 1
• 108010064785 Phospholipases Proteins 0.000 description 1
• 101000777480 Phyllodiscus semoni DELTA-alicitoxin-Pse1b Proteins 0.000 description 1
• 231100000742 Plant toxin Toxicity 0.000 description 1
• 206010035226 Plasma cell myeloma Diseases 0.000 description 1
• 108090000568 Plasmepsin II Proteins 0.000 description 1
• 241000223821 Plasmodium malariae Species 0.000 description 1
• 206010035501 Plasmodium malariae infection Diseases 0.000 description 1
• 241001505293 Plasmodium ovale Species 0.000 description 1
• 206010035502 Plasmodium ovale infection Diseases 0.000 description 1
• 101150005409 Pmch gene Proteins 0.000 description 1
• 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 1
• 239000004698 Polyethylene Substances 0.000 description 1
• 239000002202 Polyethylene glycol Substances 0.000 description 1
• 108010076039 Polyproteins Proteins 0.000 description 1
• 101710127332 Protease I Proteins 0.000 description 1
• 101000762949 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) Exotoxin A Proteins 0.000 description 1
• 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
• 101100256174 Rattus norvegicus Olah gene Proteins 0.000 description 1
• 206010038910 Retinitis Diseases 0.000 description 1
• 102100030852 Run domain Beclin-1-interacting and cysteine-rich domain-containing protein Human genes 0.000 description 1
• 101710179516 Run domain Beclin-1-interacting and cysteine-rich domain-containing protein Proteins 0.000 description 1
• 241000231739 Rutilus rutilus Species 0.000 description 1
• 108010084592 Saporins Proteins 0.000 description 1
• 206010070834 Sensitisation Diseases 0.000 description 1
• 241000270295 Serpentes Species 0.000 description 1
• 101710137500 T7 RNA polymerase Proteins 0.000 description 1
• 101150003725 TK gene Proteins 0.000 description 1
• 238000012288 TUNEL assay Methods 0.000 description 1
• 101710137710 Thioesterase 1/protease 1/lysophospholipase L1 Proteins 0.000 description 1
• 108010046075 Thymosin Proteins 0.000 description 1
• 102000007501 Thymosin Human genes 0.000 description 1
• 240000002657 Thymus vulgaris Species 0.000 description 1
• 235000007303 Thymus vulgaris Nutrition 0.000 description 1
• 241000656145 Thyrsites atun Species 0.000 description 1
• 102000004357 Transferases Human genes 0.000 description 1
• 108090000992 Transferases Proteins 0.000 description 1
• 108090000631 Trypsin Proteins 0.000 description 1
• 102000004142 Trypsin Human genes 0.000 description 1
• 108010079351 Tumor Suppressor Protein p14ARF Proteins 0.000 description 1
• 102000014384 Type C Phospholipases Human genes 0.000 description 1
• 108010079194 Type C Phospholipases Proteins 0.000 description 1
• 241000700618 Vaccinia virus Species 0.000 description 1
• 241000710772 Yellow fever virus Species 0.000 description 1
• RLAHNGKRJJEIJL-RFZPGFLSSA-N [(2r,4r)-4-(2,6-diaminopurin-9-yl)-1,3-dioxolan-2-yl]methanol Chemical compound C12=NC(N)=NC(N)=C2N=CN1[C@H]1CO[C@@H](CO)O1 RLAHNGKRJJEIJL-RFZPGFLSSA-N 0.000 description 1
• WMHSRBZIJNQHKT-FFKFEZPRSA-N abacavir sulfate Chemical compound OS(O)(=O)=O.C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1.C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 WMHSRBZIJNQHKT-FFKFEZPRSA-N 0.000 description 1
• 150000007513 acids Chemical class 0.000 description 1
• 230000006978 adaptation Effects 0.000 description 1
• 239000002671 adjuvant Substances 0.000 description 1
• 230000002411 adverse Effects 0.000 description 1
• 230000032683 aging Effects 0.000 description 1
• 239000000556 agonist Substances 0.000 description 1
• 230000006229 amino acid addition Effects 0.000 description 1
• 125000003277 amino group Chemical group 0.000 description 1
• 230000003444 anaesthetic effect Effects 0.000 description 1
• 230000036592 analgesia Effects 0.000 description 1
• 231100000659 animal toxin Toxicity 0.000 description 1
• 125000000129 anionic group Chemical group 0.000 description 1
• 239000003945 anionic surfactant Substances 0.000 description 1
• 230000003288 anthiarrhythmic effect Effects 0.000 description 1
• 230000003466 anti-cipated effect Effects 0.000 description 1
• 229940127003 anti-diabetic drug Drugs 0.000 description 1
• 230000000078 anti-malarial effect Effects 0.000 description 1
• 230000000845 anti-microbial effect Effects 0.000 description 1
• 230000000118 anti-neoplastic effect Effects 0.000 description 1
• 230000000840 anti-viral effect Effects 0.000 description 1
• 239000002220 antihypertensive agent Substances 0.000 description 1
• 229940030600 antihypertensive agent Drugs 0.000 description 1
• 230000005756 apoptotic signaling Effects 0.000 description 1
• 239000010692 aromatic oil Substances 0.000 description 1
• 229940009098 aspartate Drugs 0.000 description 1
• 235000003704 aspartic acid Nutrition 0.000 description 1
• 150000001510 aspartic acids Chemical class 0.000 description 1
• 230000002238 attenuated effect Effects 0.000 description 1
• 230000003190 augmentative effect Effects 0.000 description 1
• 238000000376 autoradiography Methods 0.000 description 1
• 210000003719 b-lymphocyte Anatomy 0.000 description 1
• 244000052616 bacterial pathogen Species 0.000 description 1
• 239000000688 bacterial toxin Substances 0.000 description 1
• 230000004888 barrier function Effects 0.000 description 1
• IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
• 239000011230 binding agent Substances 0.000 description 1
• 150000001607 bioavailable molecules Chemical class 0.000 description 1
• 239000003139 biocide Substances 0.000 description 1
• 239000013060 biological fluid Substances 0.000 description 1
• 230000033228 biological regulation Effects 0.000 description 1
• 230000005540 biological transmission Effects 0.000 description 1
• 238000004159 blood analysis Methods 0.000 description 1
• 230000023555 blood coagulation Effects 0.000 description 1
• 230000003139 buffering effect Effects 0.000 description 1
• 239000001506 calcium phosphate Substances 0.000 description 1
• 229910000389 calcium phosphate Inorganic materials 0.000 description 1
• 235000011010 calcium phosphates Nutrition 0.000 description 1
• 238000009924 canning Methods 0.000 description 1
• 239000012876 carrier material Substances 0.000 description 1
• 108010042238 caspase-activated deoxyribonuclease Proteins 0.000 description 1
• 230000006652 catabolic pathway Effects 0.000 description 1
• 238000006555 catalytic reaction Methods 0.000 description 1
• 101150055276 ced-3 gene Proteins 0.000 description 1
• 238000012832 cell culture technique Methods 0.000 description 1
• 230000022131 cell cycle Effects 0.000 description 1
• 230000012820 cell cycle checkpoint Effects 0.000 description 1
• 230000005779 cell damage Effects 0.000 description 1
• 230000003915 cell function Effects 0.000 description 1
• 208000037887 cell injury Diseases 0.000 description 1
• 230000006037 cell lysis Effects 0.000 description 1
• 239000006285 cell suspension Substances 0.000 description 1
• 238000013043 cell viability test Methods 0.000 description 1
• 230000004700 cellular uptake Effects 0.000 description 1
• 239000001913 cellulose Substances 0.000 description 1
• 229920002678 cellulose Polymers 0.000 description 1
• 229960005091 chloramphenicol Drugs 0.000 description 1
• 229960003677 chloroquine Drugs 0.000 description 1
• WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
• 208000012601 choreatic disease Diseases 0.000 description 1
• 210000003483 chromatin Anatomy 0.000 description 1
• 229960002376 chymotrypsin Drugs 0.000 description 1
• VYVRIXWNTVOIRD-UHFFFAOYSA-N ciguatoxin Natural products O1C(C(C(C)C2OC3CC(C)CC4OC5(C)C(O)CC6OC7C=CC8OC9CC%10C(C(C%11OC(C=CCC%11O%10)C=CC(O)CO)O)OC9C=CC8OC7CC=CCC6OC5CC4OC3CC2O2)O)C2C(C)C(C)C21CC(O)CO2 VYVRIXWNTVOIRD-UHFFFAOYSA-N 0.000 description 1
• LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
• 238000012411 cloning technique Methods 0.000 description 1
• 238000011260 co-administration Methods 0.000 description 1
• 238000000975 co-precipitation Methods 0.000 description 1
• 239000011248 coating agent Substances 0.000 description 1
• 238000000576 coating method Methods 0.000 description 1
• 239000003184 complementary RNA Substances 0.000 description 1
• 239000012141 concentrate Substances 0.000 description 1
• 230000021615 conjugation Effects 0.000 description 1
• 238000007596 consolidation process Methods 0.000 description 1
• 238000010276 construction Methods 0.000 description 1
• 239000000356 contaminant Substances 0.000 description 1
• 239000008120 corn starch Substances 0.000 description 1
• 238000012258 culturing Methods 0.000 description 1
• 125000004122 cyclic group Chemical group 0.000 description 1
• 208000031513 cyst Diseases 0.000 description 1
• 208000020023 cytomegalovirus pneumonia Diseases 0.000 description 1
• 229940104302 cytosine Drugs 0.000 description 1
• 238000002784 cytotoxicity assay Methods 0.000 description 1
• 231100000263 cytotoxicity test Toxicity 0.000 description 1
• 230000006735 deficit Effects 0.000 description 1
• 210000004268 dentin Anatomy 0.000 description 1
• 239000003599 detergent Substances 0.000 description 1
• 230000001627 detrimental effect Effects 0.000 description 1
• 238000010586 diagram Methods 0.000 description 1
• 239000005546 dideoxynucleotide Substances 0.000 description 1
• 230000001079 digestive effect Effects 0.000 description 1
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
• 230000008034 disappearance Effects 0.000 description 1
• 238000009826 distribution Methods 0.000 description 1
• 239000008298 dragée Substances 0.000 description 1
• 229940000406 drug candidate Drugs 0.000 description 1
• 239000003937 drug carrier Substances 0.000 description 1
• 238000009509 drug development Methods 0.000 description 1
• 238000007876 drug discovery Methods 0.000 description 1
• 230000004064 dysfunction Effects 0.000 description 1
• 235000013399 edible fruits Nutrition 0.000 description 1
• 238000004520 electroporation Methods 0.000 description 1
• 238000010828 elution Methods 0.000 description 1
• 239000003995 emulsifying agent Substances 0.000 description 1
• 239000000839 emulsion Substances 0.000 description 1
• 238000001976 enzyme digestion Methods 0.000 description 1
• 238000011067 equilibration Methods 0.000 description 1
• 210000003743 erythrocyte Anatomy 0.000 description 1
• 239000003777 experimental drug Substances 0.000 description 1
• 239000013613 expression plasmid Substances 0.000 description 1
• 238000001125 extrusion Methods 0.000 description 1
• 239000003925 fat Substances 0.000 description 1
• 150000004665 fatty acids Chemical class 0.000 description 1
• 230000002349 favourable effect Effects 0.000 description 1
• LLYJISDUHFXOHK-GOCONZMPSA-N ferroptocide Chemical compound C[C@@H]1CC[C@@]23C[C@@H](C(=O)[C@]2([C@@]1([C@@H](C[C@H]([C@@H]3C)C4=CCN5C(=O)N(C(=O)N5C4)C6=CC=CC=C6)OC(=O)CCl)C)O)O LLYJISDUHFXOHK-GOCONZMPSA-N 0.000 description 1
• 229950003499 fibrin Drugs 0.000 description 1
• 238000000799 fluorescence microscopy Methods 0.000 description 1
• 238000001215 fluorescent labelling Methods 0.000 description 1
• 235000013305 food Nutrition 0.000 description 1
• 235000019253 formic acid Nutrition 0.000 description 1
• 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
• 238000013467 fragmentation Methods 0.000 description 1
• 238000006062 fragmentation reaction Methods 0.000 description 1
• 230000002538 fungal effect Effects 0.000 description 1
• ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
• 108010027225 gag-pol Fusion Proteins Proteins 0.000 description 1
• 229960002963 ganciclovir Drugs 0.000 description 1
• IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
• 229920000159 gelatin Polymers 0.000 description 1
• 239000008273 gelatin Substances 0.000 description 1
• 235000019322 gelatine Nutrition 0.000 description 1
• 235000011852 gelatine desserts Nutrition 0.000 description 1
• 108060003196 globin Proteins 0.000 description 1
• 102000018146 globin Human genes 0.000 description 1
• 150000004676 glycans Chemical class 0.000 description 1
• 230000012010 growth Effects 0.000 description 1
• 239000001963 growth medium Substances 0.000 description 1
• 230000036541 health Effects 0.000 description 1
• 210000002216 heart Anatomy 0.000 description 1
• 238000010438 heat treatment Methods 0.000 description 1
• 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
• 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
• 102000056454 human CASP3 Human genes 0.000 description 1
• 210000005260 human cell Anatomy 0.000 description 1
• 244000052637 human pathogen Species 0.000 description 1
• 230000002209 hydrophobic effect Effects 0.000 description 1
• 230000001900 immune effect Effects 0.000 description 1
• 230000006058 immune tolerance Effects 0.000 description 1
• 238000003018 immunoassay Methods 0.000 description 1
• 230000002055 immunohistochemical effect Effects 0.000 description 1
• 239000002955 immunomodulating agent Substances 0.000 description 1
• 229940121354 immunomodulator Drugs 0.000 description 1
• 238000001114 immunoprecipitation Methods 0.000 description 1
• 238000012744 immunostaining Methods 0.000 description 1
• 229960003444 immunosuppressant agent Drugs 0.000 description 1
• 239000003018 immunosuppressive agent Substances 0.000 description 1
• 239000007943 implant Substances 0.000 description 1
• 238000000099 in vitro assay Methods 0.000 description 1
• 238000012750 in vivo screening Methods 0.000 description 1
• 230000000415 inactivating effect Effects 0.000 description 1
• 230000002779 inactivation Effects 0.000 description 1
• 208000037797 influenza A Diseases 0.000 description 1
• 208000037798 influenza B Diseases 0.000 description 1
• 238000003780 insertion Methods 0.000 description 1
• 230000037431 insertion Effects 0.000 description 1
• 238000007689 inspection Methods 0.000 description 1
• 229940079322 interferon Drugs 0.000 description 1
• 230000004068 intracellular signaling Effects 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000001990 intravenous administration Methods 0.000 description 1
• 238000011835 investigation Methods 0.000 description 1
• 238000005342 ion exchange Methods 0.000 description 1
• 239000002563 ionic surfactant Substances 0.000 description 1
• 238000001155 isoelectric focusing Methods 0.000 description 1
• 238000005304 joining Methods 0.000 description 1
• 206010023332 keratitis Diseases 0.000 description 1
• 238000002372 labelling Methods 0.000 description 1
• 229960001614 levamisole Drugs 0.000 description 1
• 239000007788 liquid Substances 0.000 description 1
• 210000004185 liver Anatomy 0.000 description 1
• 244000144972 livestock Species 0.000 description 1
• 239000000314 lubricant Substances 0.000 description 1
• 230000001926 lymphatic effect Effects 0.000 description 1
• 238000010841 mRNA extraction Methods 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• 230000014759 maintenance of location Effects 0.000 description 1
• 206010025482 malaise Diseases 0.000 description 1
• 210000005171 mammalian brain Anatomy 0.000 description 1
• 239000000463 material Substances 0.000 description 1
• 230000008774 maternal effect Effects 0.000 description 1
• 101150024647 mch gene Proteins 0.000 description 1
• 230000001404 mediated effect Effects 0.000 description 1
• 230000004060 metabolic process Effects 0.000 description 1
• 229910052751 metal Inorganic materials 0.000 description 1
• 239000002184 metal Substances 0.000 description 1
• TWXDDNPPQUTEOV-FVGYRXGTSA-N methamphetamine hydrochloride Chemical compound Cl.CN[C@@H](C)CC1=CC=CC=C1 TWXDDNPPQUTEOV-FVGYRXGTSA-N 0.000 description 1
• TWBTYFFJJKWART-UHFFFAOYSA-N methyl 2-[[4,6-bis(propan-2-ylamino)-1,3,5-triazin-2-yl]oxy]benzoate Chemical compound COC(=O)C1=CC=CC=C1OC1=NC(NC(C)C)=NC(NC(C)C)=N1 TWBTYFFJJKWART-UHFFFAOYSA-N 0.000 description 1
• 238000000520 microinjection Methods 0.000 description 1
• 238000007431 microscopic evaluation Methods 0.000 description 1
• 230000002438 mitochondrial effect Effects 0.000 description 1
• 210000001616 monocyte Anatomy 0.000 description 1
• 210000005087 mononuclear cell Anatomy 0.000 description 1
• 201000000050 myeloid neoplasm Diseases 0.000 description 1
• 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
• 210000005036 nerve Anatomy 0.000 description 1
• 238000006396 nitration reaction Methods 0.000 description 1
• 229910052757 nitrogen Inorganic materials 0.000 description 1
• QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
• 239000002736 nonionic surfactant Substances 0.000 description 1
• 230000035764 nutrition Effects 0.000 description 1
• 235000016709 nutrition Nutrition 0.000 description 1
• 238000002515 oligonucleotide synthesis Methods 0.000 description 1
• 229940127240 opiate Drugs 0.000 description 1
• 230000003287 optical effect Effects 0.000 description 1
• 230000008520 organization Effects 0.000 description 1
• 230000003204 osmotic effect Effects 0.000 description 1
• 238000012856 packing Methods 0.000 description 1
• 210000000496 pancreas Anatomy 0.000 description 1
• 239000012188 paraffin wax Substances 0.000 description 1
• 229920002866 paraformaldehyde Polymers 0.000 description 1
• 230000007170 pathology Effects 0.000 description 1
• 229960001179 penciclovir Drugs 0.000 description 1
• MCYTYTUNNNZWOK-LCLOTLQISA-N penetratin Chemical compound C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CC=CC=C1 MCYTYTUNNNZWOK-LCLOTLQISA-N 0.000 description 1
• 108010043655 penetratin Proteins 0.000 description 1
• 239000000816 peptidomimetic Substances 0.000 description 1
• 230000008447 perception Effects 0.000 description 1
• 230000002093 peripheral effect Effects 0.000 description 1
• 230000002085 persistent effect Effects 0.000 description 1
• 239000003208 petroleum Substances 0.000 description 1
• 239000008177 pharmaceutical agent Substances 0.000 description 1
• 239000008194 pharmaceutical composition Substances 0.000 description 1
• 239000000546 pharmaceutical excipient Substances 0.000 description 1
• 239000000825 pharmaceutical preparation Substances 0.000 description 1
• 238000001050 pharmacotherapy Methods 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
• 239000003123 plant toxin Substances 0.000 description 1
• 108010020708 plasmepsin Proteins 0.000 description 1
• 108700028325 pokeweed antiviral Proteins 0.000 description 1
• 108010089520 pol Gene Products Proteins 0.000 description 1
• 238000000711 polarimetry Methods 0.000 description 1
• 229920002401 polyacrylamide Polymers 0.000 description 1
• 229920001223 polyethylene glycol Polymers 0.000 description 1
• 229920001282 polysaccharide Polymers 0.000 description 1
• 239000005017 polysaccharide Substances 0.000 description 1
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
• 239000013641 positive control Substances 0.000 description 1
• 231100000683 possible toxicity Toxicity 0.000 description 1
• 229920001592 potato starch Polymers 0.000 description 1
• 230000003389 potentiating effect Effects 0.000 description 1
• 239000002244 precipitate Substances 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 238000003825 pressing Methods 0.000 description 1
• 150000003141 primary amines Chemical class 0.000 description 1
• 210000005238 principal cell Anatomy 0.000 description 1
• 230000008569 process Effects 0.000 description 1
• 210000001236 prokaryotic cell Anatomy 0.000 description 1
• 230000002062 proliferating effect Effects 0.000 description 1
• 230000002035 prolonged effect Effects 0.000 description 1
• 239000012474 protein marker Substances 0.000 description 1
• 230000030788 protein refolding Effects 0.000 description 1
• 238000001243 protein synthesis Methods 0.000 description 1
• 230000012743 protein tagging Effects 0.000 description 1
• 230000005180 public health Effects 0.000 description 1
• 230000002685 pulmonary effect Effects 0.000 description 1
• 239000010453 quartz Substances 0.000 description 1
• 229960000948 quinine Drugs 0.000 description 1
• 230000005855 radiation Effects 0.000 description 1
• 230000009467 reduction Effects 0.000 description 1
• 230000011514 reflex Effects 0.000 description 1
• 230000001850 reproductive effect Effects 0.000 description 1
• 230000008261 resistance mechanism Effects 0.000 description 1
• 230000004044 response Effects 0.000 description 1
• 230000000717 retained effect Effects 0.000 description 1
• 238000004007 reversed phase HPLC Methods 0.000 description 1
• 230000002441 reversible effect Effects 0.000 description 1
• PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
• 210000003705 ribosome Anatomy 0.000 description 1
• 108091092562 ribozyme Proteins 0.000 description 1
• 239000012266 salt solution Substances 0.000 description 1
• 238000005185 salting out Methods 0.000 description 1
• 150000003335 secondary amines Chemical class 0.000 description 1
• 230000008313 sensitization Effects 0.000 description 1
• 230000001953 sensory effect Effects 0.000 description 1
• 230000001568 sexual effect Effects 0.000 description 1
• RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
• 238000004513 sizing Methods 0.000 description 1
• 239000007787 solid Substances 0.000 description 1
• 230000009870 specific binding Effects 0.000 description 1
• 239000002708 spider venom Substances 0.000 description 1
• 210000000278 spinal cord Anatomy 0.000 description 1
• 238000009987 spinning Methods 0.000 description 1
• 210000004988 splenocyte Anatomy 0.000 description 1
• 230000002269 spontaneous effect Effects 0.000 description 1
• 238000010186 staining Methods 0.000 description 1
• 230000000638 stimulation Effects 0.000 description 1
• 238000003756 stirring Methods 0.000 description 1
• 238000003860 storage Methods 0.000 description 1
• 238000012916 structural analysis Methods 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• GECHUMIMRBOMGK-UHFFFAOYSA-N sulfapyridine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=CC=CC=N1 GECHUMIMRBOMGK-UHFFFAOYSA-N 0.000 description 1
• 239000013589 supplement Substances 0.000 description 1
• 239000000829 suppository Substances 0.000 description 1
• 239000004094 surface-active agent Substances 0.000 description 1
• 238000001356 surgical procedure Methods 0.000 description 1
• 238000013268 sustained release Methods 0.000 description 1
• 239000012730 sustained-release form Substances 0.000 description 1
• 230000002195 synergetic effect Effects 0.000 description 1
• 238000010189 synthetic method Methods 0.000 description 1
• 239000006188 syrup Substances 0.000 description 1
• 235000020357 syrup Nutrition 0.000 description 1
• 239000003826 tablet Substances 0.000 description 1
• 230000008685 targeting Effects 0.000 description 1
• 150000003512 tertiary amines Chemical class 0.000 description 1
• 229940104230 thymidine Drugs 0.000 description 1
• LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 description 1
• 239000001585 thymus vulgaris Substances 0.000 description 1
• 238000003325 tomography Methods 0.000 description 1
• 230000001988 toxicity Effects 0.000 description 1
• 231100000419 toxicity Toxicity 0.000 description 1
• 210000003437 trachea Anatomy 0.000 description 1
• 229940043263 traditional drug Drugs 0.000 description 1
• 238000003151 transfection method Methods 0.000 description 1
• 238000002054 transplantation Methods 0.000 description 1
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
• 230000001960 triggered effect Effects 0.000 description 1
• 239000003656 tris buffered saline Substances 0.000 description 1
• 239000012588 trypsin Substances 0.000 description 1
• 238000005199 ultracentrifugation Methods 0.000 description 1
• 241000701161 unidentified adenovirus Species 0.000 description 1
• 241000701447 unidentified baculovirus Species 0.000 description 1
• 241001515965 unidentified phage Species 0.000 description 1
• 210000003934 vacuole Anatomy 0.000 description 1
• 230000002792 vascular Effects 0.000 description 1
• 235000015112 vegetable and seed oil Nutrition 0.000 description 1
• 239000008158 vegetable oil Substances 0.000 description 1
• 230000029812 viral genome replication Effects 0.000 description 1
• 238000012800 visualization Methods 0.000 description 1
• 150000003722 vitamin derivatives Chemical class 0.000 description 1
• 238000005406 washing Methods 0.000 description 1
• 238000001262 western blot Methods 0.000 description 1
• 239000000080 wetting agent Substances 0.000 description 1
• 239000012130 whole-cell lysate Substances 0.000 description 1
• 229940051021 yellow-fever virus Drugs 0.000 description 1
• 239000010457 zeolite Substances 0.000 description 1
• DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1